These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37641650)

  • 41. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
    Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination therapy for obesity.
    Wilding JP
    J Psychopharmacol; 2017 Nov; 31(11):1503-1508. PubMed ID: 29132230
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Topiramate Utilization After Phentermine/Topiramate Approval for Obesity Management: Risk Minimization in the Era of Drug Repurposing.
    Sarayani A; Hampp C; Brown JD; Donahoo WT; Winterstein AG
    Drug Saf; 2022 Dec; 45(12):1517-1527. PubMed ID: 36318419
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit.
    Cunningham JW; Wiviott SD
    Clin Cardiol; 2014 Nov; 37(11):693-9. PubMed ID: 25223901
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy.
    Milano W; De Biasio V; Di Munzio W; Foggia G; Capasso A
    Endocr Metab Immune Disord Drug Targets; 2020; 20(8):1232-1243. PubMed ID: 32410565
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-obesity pharmacotherapy for treatment of pediatric type 2 diabetes: Review of the literature and lessons learned from adults.
    Bensignor MO; Kelly AS; Arslanian S
    Front Endocrinol (Lausanne); 2022; 13():1043650. PubMed ID: 36387846
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
    Shyh G; Cheng-Lai A
    Cardiol Rev; 2014; 22(1):43-50. PubMed ID: 24304809
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ACS chemical neuroscience molecule spotlight on Qnexa.
    Mercer SL
    ACS Chem Neurosci; 2011 Apr; 2(4):183-4. PubMed ID: 22778866
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release.
    Guo F; Garvey WT
    Diabetes Care; 2017 Jul; 40(7):856-862. PubMed ID: 28455281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Obesity Pharmacotherapy.
    Saunders KH; Umashanker D; Igel LI; Kumar RB; Aronne LJ
    Med Clin North Am; 2018 Jan; 102(1):135-148. PubMed ID: 29156182
    [TBL] [Abstract][Full Text] [Related]  

  • 51. THE BENEFIT OF SHORT-TERM WEIGHT LOSS WITH ANTI-OBESITY MEDICATIONS IN REAL-WORLD CLINICAL PRACTICE.
    Shibuya K; Ali KF; Ji X; Milinoivh A; Bauman J; Kattan MW; Pantalone KM; Burguera B
    Endocr Pract; 2019 Oct; 25(10):1022-1028. PubMed ID: 31241358
    [No Abstract]   [Full Text] [Related]  

  • 52. Drug treatment of obesity in the cardiovascular patient.
    Charakida M; Tousoulis D; Finer N
    Curr Opin Cardiol; 2013 Sep; 28(5):584-91. PubMed ID: 23928924
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacotherapy in pediatric obesity: current evidence and landscape.
    Singhal V; Sella AC; Malhotra S
    Curr Opin Endocrinol Diabetes Obes; 2021 Feb; 28(1):55-63. PubMed ID: 33186194
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).
    Allison DB; Gadde KM; Garvey WT; Peterson CA; Schwiers ML; Najarian T; Tam PY; Troupin B; Day WW
    Obesity (Silver Spring); 2012 Feb; 20(2):330-42. PubMed ID: 22051941
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis.
    Lei XG; Ruan JQ; Lai C; Sun Z; Yang X
    Obesity (Silver Spring); 2021 Jun; 29(6):985-994. PubMed ID: 33864346
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination Phentermine-Topiramate Extended Release for the Treatment of Binge Eating Disorder: An Open-Label, Prospective Study.
    Guerdjikova AI; Williams S; Blom TJ; Mori N; McElroy SL
    Innov Clin Neurosci; 2018 Jun; 15(5-6):17-21. PubMed ID: 30013815
    [No Abstract]   [Full Text] [Related]  

  • 57. Use of phentermine-topiramate extended release in combination with sleeve gastrectomy in patients with BMI 50 kg/m
    Ard JD; Beavers DP; Hale E; Miller G; McNatt S; Fernandez A
    Surg Obes Relat Dis; 2019 Jul; 15(7):1039-1043. PubMed ID: 31147285
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New pharmacological treatments for the management of obesity.
    Hurt RT; Edakkanambeth Varayil J; Ebbert JO
    Curr Gastroenterol Rep; 2014; 16(6):394. PubMed ID: 24828101
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
    Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
    JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current and future pharmacotherapies for obesity in children and adolescents.
    Kelly AS
    Nat Rev Endocrinol; 2023 Sep; 19(9):534-541. PubMed ID: 37337008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.